By SPC News Staff
Patients taking bimekizumab (UCB Biopharma) experienced a 50% or better improvement in signs and symptoms of psoriatic arthritis (PsA), according to an interim analysis of the BE OPTIMAL study.
The phase 3, multicenter, double-blind, placebo-controlled BE OPTIMAL study (ClinicalTrials.gov Identifier: NCT03895203) is assessing the efficacy and safety of bimekizumab in the treatment of adults with active PsA who have not taken a disease-modifying antirheumatic drug.